Revenue
2023
2024
2025
Metagenomi Therapeutics, Inc. (MGX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $25.2M | $52.3M | $44.8M |
| Research & development | $94.4M | $109.2M | $94.4M |
| Operating expenses | $121.2M | $141.2M | $123.2M |
| Operating income | −$96.0M | −$88.9M | −$78.5M |
| Net income | −$87.9M | −$78.1M | −$68.3M |
| Basic EPSper diluted share | -$2.36 | -$2.36 | -$20.05 |
| Diluted EPSper diluted share | -$2.36 | -$2.36 | -$20.05 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 5, 2026Form 4 | Wapnick PamelaChief Financial Officer | SellCommon Stock | 2.9K | $1.30 | $3.7K | 208.5K |
| Jun 5, 2026Form 4 | Irish JianSee Remarks | SellCommon Stock | 3.7K | $1.30 | $4.9K | 377.5K |
| Jun 5, 2026Form 4 | Wein MatthewSee Remarks | SellCommon Stock | 558 | $1.30 | $725.40 | 126.5K |
| Mar 5, 2026Form 4 | Wapnick PamelaChief Financial Officer | SellCommon Stock | 1.6K | $1.60 | $2.5K | 187.4K |
| Mar 5, 2026Form 4 | Wein MatthewSee Remarks | SellCommon Stock | 482 | $1.60 | $771.20 | 114.5K |